Galapagos NV balance sheet GLPGF
Cash and investments were $40.0 million.
USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.
| Line |
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2019
Dec 31, 2019
|
FY 2018
Dec 31, 2018
|
FY 2017
Dec 31, 2017
|
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash |
40
-0.7%
|
40
+16.8%
|
34
-64.5%
|
97
-88.0%
|
808
|
657
+105.0%
|
320
+32.8%
|
241
|
| Cash and investments |
40
-0.7%
|
40
+16.8%
|
34
-64.5%
|
97
-88.0%
|
808
|
657
+105.0%
|
320
+32.8%
|
241
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LKFT (Nasdaq), GLPGF (OTC)
- Incorporated in
- Belgium
- Headquarters
- 2800 Mechelen
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1421876
- Former names
- GALAPAGOS NV (until May 6, 2026)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.